Market PharmaPoint: Insomnia , Global Drug Forecast and Market Analysis to 2023
Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomo’s Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need. Read Complete Report with TOC: http://www.marketresearchstore.com/report/pharmapoint-insomnia-global-drug-forecast-and-market-13806
Insomnia is the most common sleep disorder and is believed to affect approximately 35% of the global population. The condition can be defined as patient-reported difficultly with sleep initiation or sleep maintenance which can include frequent awakenings, difficulty returning to sleep after awakenings, or awakening too early with inability to return to sleep. Cases of insomnia can be classified on the basis of etiology into primary and secondary (or comorbid) subtypes. The insomnia market is widely genericized creating a competitive environment for new products. As such, the treatment algorithm centers on the generically available nonbenzodiazepines and low-dose sedating antidepressants, despite the launch of numerous novel agents. The value of the insomnia market is set to further decline following the loss of exclusivity for Sunovion/Dainippon Sumitomo’s Lunesta, the top selling insomnia drug, in April 2014. However, GlobalData expects the launch of two pipeline products from a novel class of drugs to provide growth in the insomnia market as they may address some of the unmet need.
Read Complete Report with TOC: http://www.marketresearchstore.com/report/pharmapoint-insomnia-global-drug-forecast-and-market-13806
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
‣ The main driver of growth in the insomnia market will be the<br />
introduction of the orexin recep<strong>to</strong>r antagonists over the<br />
forecast period. The launch of this novel drug class may<br />
address some of the unmet need in the insomnia market due <strong>to</strong><br />
the safety profile of these drugs <strong>and</strong> the availability of longterm<br />
clinical trial data.<br />
‣ The generic erosion of Lunesta within the insomnia market will<br />
lead <strong>to</strong> a decline in market size prior <strong>to</strong> the entry of pipeline<br />
products. The availability of generic eszopiclone could greatly<br />
affect the treatment algorithm <strong>and</strong> will put downward pricing<br />
pressure on the controlled-release zolpidem generics.<br />
‣ The biggest barrier for growth in the insomnia market will be
Change language